Skip to main content
Premium Trial:

Request an Annual Quote

Sequoia Genetics Teams with Russian Academy on NGS-based Neonatal Dx

NEW YORK (GenomeWeb News) – Sequoia Genetics today said that it has partnered with the Research Centre of Medical Genetics of the Russian Academy of Medical Sciences to develop next-generation sequencing-based neonatal diagnostics.

The goal of the alliance is to develop a molecular diagnostic test for three inherited diseases that are included in obligatory newborn screening programs in Russia. Sequoia said that researchers involved in the project are developing a high-throughput assay that will detect all clinically relevant mutations in genes associated with cystic fibrosis, phenylketonuria, and galactosemia.

Alexander Pavlov, CEO of Sequoia Genetics, said that the firm will use the assay to carry out testing of clinical samples provided by the RCMG. Specialists from Sequoia and the RCMG will jointly interpret the results to determine clinical efficacy of the assay, he said.

Sequoia is a member of the Saint Petersburg, Russia-based Alkor Bio group of companies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.